MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Danaher Corp

Geschlossen

BrancheGesundheitswesen

197.94 -3.52

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

197.71

Max

204.96

Schlüsselkennzahlen

By Trading Economics

Einkommen

268M

1.1B

Verkäufe

738M

6.5B

KGV

Branchendurchschnitt

38.752

63.778

EPS

2.14

Dividendenrendite

0.62

Gewinnspanne

16.611

Angestellte

61,000

EBITDA

-230M

1.4B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+28.05% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.62%

2.39%

Nächstes Ergebnis

22. Apr. 2025

Nächste Dividendenausschüttung

25. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-16B

147B

Vorheriger Eröffnungskurs

201.46

Vorheriger Schlusskurs

197.94

Nachrichtenstimmung

By Acuity

26%

74%

61 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Danaher Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Feb. 2025, 12:54 UTC

Ergebnisse

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29. Jan. 2025, 11:44 UTC

Ergebnisse

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22. Okt. 2024, 10:35 UTC

Ergebnisse

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

23. Juli 2024, 10:55 UTC

Ergebnisse

Danaher Expects 3Q Core Sales Drop, Backs 2024 Guidance

29. Jan. 2025, 15:25 UTC

Market Talk
Ergebnisse

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29. Jan. 2025, 13:56 UTC

Top News
Ergebnisse

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29. Jan. 2025, 11:08 UTC

Ergebnisse

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29. Jan. 2025, 11:07 UTC

Ergebnisse

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29. Jan. 2025, 11:07 UTC

Ergebnisse

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29. Jan. 2025, 11:02 UTC

Ergebnisse

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29. Jan. 2025, 11:01 UTC

Ergebnisse

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29. Jan. 2025, 11:01 UTC

Ergebnisse

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29. Jan. 2025, 11:00 UTC

Ergebnisse

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29. Jan. 2025, 11:00 UTC

Ergebnisse

Danaher 4Q Cont Ops EPS $1.49 >DHR

29. Jan. 2025, 11:00 UTC

Ergebnisse

Danaher 4Q Net $1.09B >DHR

29. Jan. 2025, 11:00 UTC

Ergebnisse

Danaher 4Q EPS $1.49 >DHR

29. Jan. 2025, 11:00 UTC

Ergebnisse

Danaher 4Q Adj EPS $2.14 >DHR

29. Jan. 2025, 11:00 UTC

Ergebnisse

Danaher 4Q Sales $6.5B >DHR

22. Okt. 2024, 10:02 UTC

Ergebnisse

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22. Okt. 2024, 10:02 UTC

Ergebnisse

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

22. Okt. 2024, 10:01 UTC

Ergebnisse

Danaher Sees 4Q Adjusted Core Revenue Down Low-Single Digits >DHR

22. Okt. 2024, 10:00 UTC

Ergebnisse

Danaher 3Q Operating Cash Flow $1.5B, Adjusted Free Cash Flow $1.2B >DHR

22. Okt. 2024, 10:00 UTC

Ergebnisse

Danaher 3Q Sales $5.8B >DHR

22. Okt. 2024, 10:00 UTC

Ergebnisse

Danaher 3Q EPS $1.12 >DHR

22. Okt. 2024, 10:00 UTC

Ergebnisse

Danaher 3Q Adj EPS $1.71 >DHR

22. Okt. 2024, 10:00 UTC

Ergebnisse

Danaher 3Q Net $818M >DHR

22. Okt. 2024, 10:00 UTC

Ergebnisse

Danaher 3Q Cont Ops EPS $1.12 >DHR

23. Juli 2024, 12:39 UTC

Top News
Ergebnisse

Danaher Stock Surges. More Than Earnings Are Driving It Higher. -- Barrons.com

23. Juli 2024, 10:05 UTC

Ergebnisse

Danaher 2Q Adjusted Core Revenue Fell 3.5% >DHR

23. Juli 2024, 10:05 UTC

Ergebnisse

Danaher Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Peer-Vergleich

Kursveränderung

Danaher Corp Prognose

Kursziel

By TipRanks

28.05% Vorteil

12-Monats-Prognose

Durchschnitt 262.71 USD  28.05%

Hoch 300 USD

Tief 240 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Danaher Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

17 ratings

13

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

199.78 / 210.26Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

61 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.